Sickle Cell Disease Treatment Market (2018-2023) Size, Share & Trends Analysis Featuring Emmaus Life Sciences, Global Blood Therapeutics, Bluebird Bio, Pfizer, and Novartis - ResearchAndMarkets.com

September 24, 2018

DUBLIN--(BUSINESS WIRE)--Sep 24, 2018--The “Sickle Cell Disease Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant), By Major Markets, Vendor Landscape, And Segment Forecasts, 2018 - 2023” report has been added to ResearchAndMarkets.com’s offering.

The global sickle cell disease treatment market size is expected to reach USD 5.5 billion by 2023, exhibiting a 14.3% CAGR during the forecast period. Several factors such as increase in investments for R&D, growing target population, and favorable government initiatives are anticipated to drive the market.

High unmet medical needs, strong pipeline, and growing patient pool are key factors expected to influence market growth. In recent years, demand for cost-effective drugs and gene therapies for SCD has increased owing to unavailability of a permanent cure and risks associated with bone marrow transplant.

Expected launch of late-stage pipeline drugs such as voxelotor, crizanlizumab, Altemia, and rivipansel is projected to drive the sickle cell disease market during the forecast period. Healthcare initiatives undertaken by respective economies are crucial for curbing the financial burden of the disease as well as for increasing access to healthcare facilities and providing various services for early diagnosis, subsequent treatment, and palliative care.

Further key findings from the report suggest:

Currently, 20 to 25 million people worldwide are reportedly living with sickle cell disease and about 300,000 infants are born annually with the disease. U.S. dominated the global market and is projected to maintain its position through 2023, owing to rise in incidence of diseases and launch of promising pipeline candidates. Among treatments, blood transfusion held the largest share in 2017, followed by pharmacotherapy. However, it is anticipated that pharmacotherapy will lead the market by 2023, supported by a strong pipeline and several promising drug launches. Emmaus Medical, Global Blood Therapeutics, Bluebird Bio, Pfizer, and Novartis are some of the key players operating in this market. Emmaus Medical is projected to dominate the SCD pharmaceutical market in 2023, supported by strong sales of Endari Currently, 37 pipeline drugs are in various clinical development stages and significant sales contribution is expected from promising candidates such as voxelotor (Global Blood Therapeutics), crizanlizumab (Novartis), Altemia (Sancilio), and rivipansel (Pfizer). Companies ProfiledEmmaus Life SciencesGlobal Blood TherapeuticsBluebird BioPfizerNovartis

Key Topics Covered

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology

Chapter 4 Global Sickle Cell Disease Market Overview

Chapter 5 Global Sickle Cell Disease Market: Pipeline Intelligence

Chapter 6 Company Profiles

Chapter 7 Market Outlook

For more information about this report visit https://www.researchandmarkets.com/research/w7nzx2/sickle_cell?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180924005640/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Hematological Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/24/2018 10:48 AM/DISC: 09/24/2018 10:48 AM


Update hourly